Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase

Published 2016 View Full Article

Authors

Keywords

pantoprazole, PPI, TOPK, cell transformation, colon carcinoma

Journal

Oncotarget

Volume 7, Issue 16, Pages -

Publisher

Impact Journals, LLC

Online

2016-03-08

DOI

10.18632/oncotarget.7984

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More